Publications for Mikael Chéramy
Co-author map based on ISI articles 2007-
Publications mentioned in social media 3 times*
Journal Articles
Mikael Chéramy, Christiane S. Hampe, Johnny Ludvigsson and Rosaura Casas
Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
Clinical and Experimental Immunology, 2013, 171(3), 247-254.
Fulltext  |
Mikael Pihl, Linda Åkerman, Stina Axelsson, Mikael Chéramy, Maria Hjorth, R. Mallone, Johnny Ludvigsson and Rosaura Casas
Regulatory T cell phenotype and function 4 years after GADalum treatment in children with type 1 diabetes
Clinical and Experimental Immunology, 2013, 172(3), 394-402.
|
Camilla Skoglund, Mikael Chéramy, Rosaura Casas, Johnny Ludvigsson and Christiane S Hampe
GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
Pediatric Diabetes, 2012, 13(3), 244-250.
Web of Science® Times Cited: 1 |
Mikael Pihl, Mikael Chéramy, Jenny Mjösberg, Johnny Ludvigsson and Rosaura Casas
Increased expression of regulatory T cell-associated markers in recent-onset diabetic children
Open Journal of Immunology, 2011, 1(3), 57-64.
|
Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Åkerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson and Rosaura Casas
Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
PLoS ONE, 2011, 6(12), .
Fulltext Web of Science® Times Cited: 6 |
Johnny Ludvigsson, Maria Hjorth, Mikael Chéramy, Stina Axelsson, Mikael Pihl, G Forsander, N-O Nilsson, B-O Samuelsson, T Wood, J Aman, E Ortqvist and Rosaura Casas
Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
DIABETOLOGIA, 2011, 54(3), 634-640.
Fulltext Web of Science® Times Cited: 20 |
Mikael Chéramy, Camilla Skoglund, Ingela Johansson, Johnny Ludvigsson, Christiane S Hampe and Rosaura Casas
GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response
Clinical Immunology, 2010, 137(1), 31-40.
Fulltext Web of Science® Times Cited: 16 |
Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson, Agne Lindh, NO Nilsson, Jan Åman, Eva Örtqvist, Peter Zerhouni and Rosaura Casas
GAD treatment and insulin secretion in recent-onset type 1 diabetes
New England Journal of Medicine, 2008, 359(18), 1909-1920.
Web of Science® Times Cited: 191 |
Conference Articles
E Martinuzzi, M C Gagnerault, S Fourlanos, L Harrison, Stina Axelsson, Mikael Chéramy, Johnny Ludvigsson, Rosaura Casas and R Mallone
Why are the benefits of vaccinations in the helping of beta-cellular antigenes in type 1 diabetes so limited? An analysis of linked immunological biomarkers in DIABETES and METABOLISM, vol 38, issue 2, pp A5-A5
DIABETES and METABOLISM, 2012.
|
Rosaura Casas, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl and Johnny Ludvigsson
Specific immunomodulatory effect of GAD(65) in type 1 diabetics
in DIABETOLOGIA, vol 52, 2009.
|
Johnny Ludvigsson, Camilla Skoglund, Mikael Chéramy, Rosaura Casas and C Hampe
GAD(65) treatment induces high GADA but no changes in epitopes or adverse signs/symptoms in type 1 diabetic children
in DIABETOLOGIA, vol 52., 2009.
|
Ph.D. Theses
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
